Table 4. Odds ratios and 95% confidence intervals for bladder cancer risk and LINE-1%5mC by gender and smoking status in PLCO.
NEVER SMOKER | EVER SMOKER | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
Gender | N Case | N Control |
OR2 | 95% CI2 | P2 | N Case | N Control | OR2 | 95% CI2 | P2 |
Male | ||||||||||
Q11 | 13 | 49 | REF | - | - | 36 | 92 | FER | - | - |
Q2 | 12 | 49 | 0.91 | 0.36–2.28 | 0.84 | 50 | 82 | 1.77 | 1.02–3.10 | 0.04 |
Q3 | 15 | 63 | 0.92 | 0.40–2.13 | 0.84 | 62 | 88 | 2.03 | 1.18–3.50 | 0.01 |
Q4 | 13 | 58 | 0.79 | 0.33–1.91 | 0.60 | 41 | 79 | 1.64 | 0.91–2.94 | 0.10 |
P-trend | 0.63 | 0.07 | ||||||||
P-interaction | 0.56 | |||||||||
Q1 | 13 | 49 | REF | - | - | 36 | 92 | REF | - | - |
Q2–Q4 | 40 | 170 | 0.88 | 0.43–1.78 | 0.71 | 153 | 249 | 1.83 | 1.14–2.95 | 0.01 |
P-interaction | 0.16 | |||||||||
Female | ||||||||||
Q1 | 7 | 22 | 1.00 | - | - | 12 | 15 | |||
Q2 | 2 | 18 | 0.35 | 0.06–1.91 | 0.23 | 5 | 2 | 1.43 | 0.21–9.98 | 0.72 |
Q3 | 7 | 23 | 0.95 | 0.29–3.14 | 0.93 | 12 | 6 | 2.55 | 0.57–11.46 | 0.22 |
Q4 | 6 | 22 | 0.84 | 0.24–2.91 | 0.78 | 6 | 8 | 1.06 | 0.25–4.47 | 0.94 |
P-trend | 0.99 | 0.61 | ||||||||
P-interaction | 0.35 | |||||||||
Q1 | 7 | 22 | 1.00 | - | - | 12 | 15 | 1.00 | - | - |
Q2-Q4 | 15 | 63 | 0.74 | 0.27–2.03 | 0.55 | 23 | 16 | 1.63 | 0.54–4.93 | 0.39 |
P-interaction | 0.27 |
N, number; OR, odds ratio; CI, confidence interval; PLCO, Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. 1Quartile cutpoints were based on sex-specific control distributions: PLCO males, 78.3: <82.9, <84.3, <85.7, ≤89.7%; females, 78.4: <82.7, <83.4, <84.9, ≤89.5%. 2Regression models adjusted for age at blood draw, packyears smoking, study center.